NCT02358421

Brief Summary

Polycystic ovarian syndrome (PCOS) patients have an increased risk of ovarian hyperstimulation syndrome (OHSS) after assisted reproduction techniques (ART). In addition, these women have a high risk of develop further metabolic disorders. Rotterdam criteria defined by the European Society of Human Reproduction and Endocrinology (ESHRE) are used for the diagnosis of PCOS. The aim of this study is both to determine the prevalence of PCOS in infertile patients who require ART in our Center and to evaluate the usefulness of each specific diagnosis criterium within Rotterdam criteria of PCOS as predictor of risk of OHSS. It also seeks to establish a cohort of patients identified according to specific Rotterdam criteria of PCOS to assess the incidence of long term complications.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 21, 2014

Completed
11 months until next milestone

First Posted

Study publicly available on registry

February 9, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

February 9, 2015

Status Verified

January 1, 2015

Enrollment Period

1.7 years

First QC Date

March 21, 2014

Last Update Submit

February 3, 2015

Conditions

Keywords

Rotterdam's diagnostic criteria of PCOSRisk of OHSS

Outcome Measures

Primary Outcomes (1)

  • Sensitivity, specificity, negative and positive predictive values of each inclusion criteria (independently and combined) to predict OHSS and high ovarian response after ART

    18 months

Secondary Outcomes (3)

  • Prevalence of metabolic syndrome in the cohort of included patients

    After COH for ART

  • Incidence of metabolic syndrome in patients with at least one criterion of PCOS

    15 years in average

  • Incidence of cardiiovascular events in patients with at least one criterion of PCOS

    15 years in average

Study Arms (1)

Initial cohort

Patients at risk of developing OHSS according to the inclusion criteria

Eligibility Criteria

Age18 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients with primary infertility at risk of developing ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. This population was defined according to the presence of at least one Rotterdam criterion or the presence of an abnromal luteal phase, invesion of the FSH/LH ratio or an increased AMH level (see inclusion and exclusion criteria below)

You may qualify if:

  • Patients with primary infertility undergoing ovarian stimulation for IVF/ICSI plus one of the following criteria:
  • Ovulation dysfunction.
  • Androgen excess: clinical and/or biochemical.
  • Polycystic ovary by transvaginal ultrasound in early follicular phase.
  • AMH\>35 pmol/l
  • FSH/LH\<1
  • P4 levels on the day of menstrual cycle \<10ng/ml and cycle duration \<26 days
  • Patients who undergo a second cycle after a previous one in which they were considered high responders (the cycle was canceled due to high risk of OHSS or the patient underwent coasting)

You may not qualify if:

  • Age \<18 or \>39 years
  • FSH \>10
  • Uterine fibroids requiring surgery
  • Diagnosis of hyperprolactinemia , hypothyroidism, congenital adrenal hyperplasia, Cushing's syndrome, ovarian tumors, adrenal tumors or hypogonadotropic hypogonadism
  • Intake of oral contraceptives three months prior to the completion of IVF
  • Diagnosis of endometriosis (by ultrasound or surgical findings)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

La Fe University Hospital

Valencia, Valencia, 46026, Spain

RECRUITING

Study Officials

  • Vicente Montañana-Ramirez, MD, PhD

    Instituto de Investigaciones Sanitarias La Fe

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Vicente Montañana-Ramírez, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
30 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2014

First Posted

February 9, 2015

Study Start

October 1, 2013

Primary Completion

July 1, 2015

Study Completion

December 1, 2015

Last Updated

February 9, 2015

Record last verified: 2015-01

Locations